Shane D Gallagher

Faculty

Shane Gallagher headshot

Shane D Gallagher

DNP PMHNP-BC

Clinical Assistant Professor
Associate Program Director, Psychiatric-Mental Health NP
Associate Program Director, Specialty Sequence in Substance Use and Addictive Disorders

1 212 998 5338

433 FIRST AVENUE
NEW YORK, NY 10010
United States

Shane Gallagher, DNP, PMHNP-BC is a clinical assistant professor at NYU Rory Meyers College of Nursing. His research interests include evidence-based interventions for substance use disorders, trauma-informed treatment modalities, educating providers on motivational interviewing, and optimizing healthcare systems with implementation science principles.

Gallagher is a co-investigator on a National Institute on Drug Abuse (NIDA) grant-funded, multi-site, randomized implementation trial examining strategies for engagement with medication for opioid use disorder after hospital discharge. He provides technical assistance and practice facilitation to interdisciplinary, hospital-based, substance-use treatment teams across New York state.

Before joining NYU Meyers, Gallagher had over a decade of patient care experience in two academic medical centers. He started as a care coordinator at Memorial Sloan Kettering Cancer Center, contributing to interdisciplinary chemotherapy operations teams. He then became a registered nurse on the gastrointestinal oncology service, working both as an inpatient, medical-surgical nurse, and an outpatient chemotherapy infusion nurse. He was a psychiatric nurse practitioner at Bellevue Hospital, working on the inpatient psychiatry units and consultation-liaison service. During that time, he developed a formalized clinical training program for psychiatric nurse practitioner graduate students. He was a research clinician at the NYU Grossman School of Medicine, working on a national study examining the treatment of opioid use disorder.

Among his many honors, Gallagher received the 2021 award for the overall distinguished DNP graduate at New York University. He was inducted into the Sigma Theta Tau Honors Society in Nursing at Columbia University in 2015. He received the 2009 David Weinberg Memorial award for community service and was inducted to Phi Beta Kappa at Binghamton University.

Gallagher earned his DNP from NYU Meyers, BSN/MSN from Columbia University, and BA from Binghamton University.

DNP - New York University
MSN - Columbia University
BSN - Columbia University
BA - Binghamton University

American Nurses Association
American Association of Nurse Practitioners
American Psychiatric Nurses Association

Overall Distinguished DNP graduate, New York University (2021)
David Weinberg Memorial Award in Community Service, Binghamton University (2009)
University Award for Undergraduate Student Excellence, Binghamton University (2008)

Sensitivity of Medicaid Claims Data for Identifying Opioid Use Disorder in Patients Admitted to 6 New York City Public Hospitals

Mcneely, J., Gallagher, S. D., Mazumdar, M., Appleton, N., Fernando, J., Owens, E., Bone, E., Krawczyk, N., Dolle, J., Marcello, R. K., Billings, J., & Wang, S. (2023). Journal of Addiction Medicine, 17(3), 339-341. 10.1097/ADM.0000000000001097
Abstract
Abstract
Objectives Behavioral health diagnoses are frequently underreported in administrative health data. For a pragmatic trial of a hospital addiction consult program, we sought to determine the sensitivity of Medicaid claims data for identifying patients with opioid use disorder (OUD). Methods A structured review of electronic health record (EHR) data was conducted to identify patients with OUD in 6 New York City public hospitals. Cases selected for review were adults admitted to medical/surgical inpatient units who received methadone or sublingual buprenorphine in the hospital. For cases with OUD based on EHR review, we searched for the hospitalization in Medicaid claims data and examined International Classification of Diseases, Tenth Revision discharge diagnosis codes to identify opioid diagnoses (OUD, opioid poisoning, or opioid-related adverse events). Sensitivity of Medicaid claims data for capturing OUD hospitalizations was calculated using EHR review findings as the reference standard measure. Results Among 552 cases with OUD based on EHR review, 465 (84.2%) were found in the Medicaid claims data, of which 418 (89.9%) had an opioid discharge diagnosis. Opioid diagnoses were the primary diagnosis in 49 cases (11.7%), whereas in the remainder, they were secondary diagnoses. Conclusion In this sample of hospitalized patients receiving OUD medications, Medicaid claims seem to have good sensitivity for capturing opioid diagnoses. Although the sensitivity of claims data may vary, it can potentially be a valuable source of information about OUD patients.